| Drugs by Condition |  |
Chronic Lymphocytic Leukemia (CLL) Medications
Drugs associated with Chronic Lymphocytic Leukemia (CLL)
The following drugs and medications are in some way related to, or used in the treatment of Chronic Lymphocytic Leukemia (CLL).
This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Chronic Lymphocytic Leukemia (CLL) Medications in the Pipeline
Genasense (oblimersen sodium)
- July 14, 2008
FDA Accepts Genta's NDA Amendment as Complete Response for Genasense Treatment of Chronic Lymphocytic Leukemia - June 6, 2008
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia - March 17, 2008
FDA Indicates That Genasense Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data - January 14, 2008
FDA Extends Review of Genasense NDA Appeal in Chronic Lymphocytic Leukemia - October 25, 2007
Genta Completes Appeal of FDA Decision for Genasense in CLL - April 4, 2007
Genta Appeals FDA Decision on Genasense in CLL - February 6, 2007
Genta Announces the Company Will Appeal FDA Action on New Drug Application of Genasense in Chronic Lymphocytic Leukemia - December 15, 2006
Genta Receives Non-Approvable Notice for Application of Genasense in Patients With Chronic Lymphocytic Leukemia - October 30, 2006
FDA Extends Review Period for Genasense New Drug Application in Chronic Lymphocytic Leukemia - September 5, 2006
Briefing Documents Posted for FDA Committee Review of Genasense New Drug Application - July 27, 2006
Genta Announces FDA's Oncology Drug Advisory Committee Will Review Genasense as Treatment for Chronic Lymphocytic Leukemia - March 1, 2006
Genasense New Drug Application Accepted for Review by FDA - December 29, 2005
Genta Files New Drug Application for FDA Approval of Genasense Plus Chemotherapy for Patients with Advanced or Refractory Chronic Lymphocytic Leukemia - June 30, 2005
Genta Initiates New Drug Application for Genasense in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia - May 13, 2004
Genta Announces Withdrawal of New Drug Application for Genasense in Melanoma - May 3, 2004
FDA Advisory Committee Reviews Genasense For Use in Advanced Melanoma - April 20, 2004
Genta and Aventis Announce Genasense Expanded Access Program for Patients with Advanced Melanoma - February 6, 2004
Aventis and Genta Announce FDA Acceptance and Priority Review of New Drug Application for Genasense in Advanced Melanoma
Oral Fludarabine (fludarabine phosphate)
See also
Learn more about Chronic Lymphocytic Leukemia (CLL)
Medical encyclopedia results for:
